Therapeutics
Tamer Group produces diversified therapeutics comprising novel generics and innovative technologies covering urology, cardiovascular, diabetes, oncology, specialty primary care and nutraceuticals.
Full-service solutions
Production capacity encompasses a full range of dosage forms, blending, tableting, encapsulation, inspection, coating and automated packaging.
SAJA
SAJA is a 50-year joint venture, licensing and supplying agreement with Astellas and Daiichi-Sankyo Co. Ltd. producing the latest researched pharmaceutical products for the Saudi, GCC, Yemen, and Levant markets.
Visit WebsiteInnovation first
SAJA provides diversified products comprising novel generics and innovative technologies within a unique portfolio, covering urology, cardiovascular, diabetes, oncology, specialty primary care and nutraceuticals.
Manufacturing
The SAJA pharmaceutical manufacturing facility is a 32,000 sq. m. site producing solid dosage forms, as well as granulation, blending, tableting, encapsulation, inspection, coating and automated packaging.
Tamer Mölnlycke Care
Tamer Mölnlycke Care: a Joint Venture between Mölnlycke Healthcare AB (Sweden) and Tamer Group to manufacture customized procedural trays (ProcedurePak®) that will increase efficiency and reduce waste across healthcare service providers in the MENA region.
Visit WebsiteFrom import to local manufacture
Tamer Group previously imported these trays to Saudi Arabia, but the JV with Mölnlycke means these are now produced locally, leading to quicker turnaround times.
Saving time and resources
In the operating room, custom procedure trays offer a significant time saving of 40- 55%. They give surgeons more control, create less waste, and lead to better hygiene compared to other products.
Arabio
Developed by Jeddah Bio City and prominent Saudi institutions, ARABIO (Arab Company for Pharmaceutical Products) is a pharmaceutical project producing vaccines and serum for Saudi Arabia and neighbouring countries in the MENA region. Tamer Group is a shareholder of ARABIO.
A strategic national initiative
The Saudi Arabian government considers vaccine programmes a vital strategic commodity that should be available in the event of a crisis or pandemic. Arabio has opened the first vaccine production facility in the Middle East, ensuring the health and safety of populations.
First biological manufacturing in the GCC
ARABIO is an emerging niche in biopharmaceuticals and a pioneer in the Gulf Cooperation Council (GCC) medical sector. Representing the continuing success of the company, ARABIO’s Steering Committee has concluded a technology transfer with Novartis.
